NeuroSense Therapeutics Ltd (NASDAQ:NRSN) shares, rose in value on Thursday, April 16, with the stock price up by 0.22% to the previous day’s close as strong demand from buyers drove the stock to $1.03.
Actively observing the price movement in the last trading, the stock closed the session at $1.03, falling within a range of $0.98 and $1.07. The value of beta (5-year monthly) was 1.345. Referring to stock’s 52-week performance, its high was $1.64, and the low was $0.51. On the whole, NRSN has fluctuated by -3.51% over the past month.
With the market capitalization of NeuroSense Therapeutics Ltd currently standing at about $24.79 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Apr-06.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NRSN’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the price of NRSN currently trading nearly 2.37% and -3.84% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 50.00, while the 7-day volatility ratio is showing 8.46% which for the 30-day chart, stands at 8.99%. Furthermore, NeuroSense Therapeutics Ltd (NRSN)’s beta value is 1.25, and its average true range (ATR) is 0.09.
A comparison of NeuroSense Therapeutics Ltd (NRSN) with its peers suggests the former has fared considerably weaker in the market. NRSN showed an intraday change of 0.22% in last session, and over the past year, it shrunk by -37.38%%.
Data on historical trading for NeuroSense Therapeutics Ltd (NASDAQ:NRSN) indicates that the trading volumes over the past 10 days have averaged 0.13 and over the past 3 months, they’ve averaged 155.47K. According to company’s latest data on outstanding shares, there are 23.23 million shares outstanding.
Nearly 31.12% of NeuroSense Therapeutics Ltd’s shares belong to company insiders and institutional investors own 2.70% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 0.29 million shares as on 2025-03-31, resulting in a short ratio of 1.68. According to the data, the short interest in NeuroSense Therapeutics Ltd (NRSN) stood at 144.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 0.23 million. The stock has fallen by -13.89% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NRSN stock heading into the next quarter.
